The U.S. Food and Drug Administration’s (FDA) Safety Information and Adverse Event Reporting System (MedWatch) issued a safety alert that the use of “fecal transplants” (FMT) to treat Clostridium difficile infections could lead to SARS-CoV-2 transmission.
According to the report, recent data indicate the presence of SARS-CoV-2 virus RNA and/or SARS-CoV-2 virus in the feces of patients with corolla pneumonia (COVID-19), indicating that the SARS-CoV-2 virus may be transmitted through FMT. At present, SARS-CoV-2 cannot be widely detected in nasopharyngeal specimens of fecal donors, and there is limited information on the sensitivity of SARS-CoV-2 virus in faeces directly.
The FDA directs health care providers to implement the following protectionmeasures for FMTs that donate feces after December 1, 2019: to screen for donors to identify donors who may or may have recently been infected with SARS-CoV-2;
The FDA requires that any adverse events or side effects associated with the use of FMT be reported to MedWatch.
Fecal transplantation is a way to treat disease by reconstructing intestinal flora. That is, the treatment of healthy people’s feces, poured into the patient’s intestines, the operation process needs to be carried out through rigorous screening and experimental programs.